WecLac® Strains-Wecare Probiotics

Home
Products
Products

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
News
News

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Company News
- Industry Insight
About Us
About Us

We are leaders in microbiome research, with a focus on probiotic strains, starter cultures, and the influence of beneficial microbial communities on diverse hosts, including humans, animals, and plants.
Founder
Founder

We actively participate in international probiotic industry seminars and conferences, sharing our research results and industry insights with leading experts and peers around the world.
- Dr. Frank Fang
Contact Us
Contact Us

We welcome the opportunity to connect with you, share more insights, explore potential partnerships, and work together to drive innovation and growth in the probiotic industry.
- Contact Us
- Join Us

English Français Español Русский

Home > Products > WecLac^® Strains > Bifidobacterium animalis subsp. lactis

Bifidobacterium animalis subsp. lactisBLa80

Potency

600B CFU/g

Source of Strain

Healthy breast milk samples

Deposit Number

PTA-126817(ATCC) No.22547(CGMCC)

Functions

Gastrointestinal Health
Metabolic Health
Emotional Health
Maternal & Child Health
Immune Health
Oral Health

References

[1]Zhao TS, Xie LW, Cai S, Xu JY, Zhou H, Tang LF, Yang C, Fang S, Li M, Tian Y. Dysbiosis of Gut Microbiota Is Associated With the Progression of Radiation-Induced Intestinal Injury and Is Alleviated by Oral Compound Probiotics in Mouse Model. Front Cell Infect Microbiol. 2021 Oct 25;11:717636. doi: 10.3389/fcimb.2021.717636. PMID: 34760714; PMCID: PMC8573182.

[2]Dong Y, Liao W, Tang J, Fei T, Gai Z, Han M. Bifidobacterium BLa80 mitigates colitis by altering gut microbiota and alleviating inflammation. AMB Express. 2022 Jun 7;12(1):67. doi: 10.1186/s13568-022-01411-z. PMID: 35670877; PMCID: PMC9174416.

[3]Dong Y, Han M, Fei T, Liu H, Gai Z. Utilization of diverse oligosaccharides for growth by Bifidobacterium and Lactobacillus species and their in vitro co-cultivation characteristics. Int Microbiol. 2023 Nov 9. doi: 10.1007/s10123-023-00446-x. Epub ahead of print. PMID: 37946011.

[4]Chen K, Jin S, Ma Y, Cai L, Xu P, Nie Y, Luo L, Yu Q, Shen Y, Zhou Z, Liu C. Adjudicative efficacy of Bifidobacterium animalis subsp. lactis BLa80 in treating acute diarrhea in children: a randomized, double-blinded, placebo-controlled study. Eur J Clin Nutr. 2024 Mar 11. doi: 10.1038/s41430-024-01428-6. Epub ahead of print. PMID: 38467857.

[5]JanssenDuijghuijsen L, van den Belt M, Rijnaarts I, Vos P, Guillemet D, Witteman B, de Wit N. Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. Eur J Nutr. 2024 Apr 23. doi: 10.1007/s00394-024-03398-8. Epub ahead of print. PMID: 38653808.

[6]Wu, CaiyunLi, TianlinQi, JingJiang, TianXu, HuaideLei, Hongjie.Effects of lactic acid fermentation-based biotransformation on phenolic profiles, antioxidant capacity and flavor volatiles of apple juice[J].LWT-Food Science & Technology, 2020, 122.

[7]Zhu M, Zhu J, Fang S, Zhao B. Complete Genome Sequence of Bifidobacterium animalis subsp. lactis BLa80, a Strain Isolated from Human Breast Milk. Microbiol Resour Announc. 2023 Jun 20;12(6):e0046522. doi: 10.1128/mra.00465-22. Epub 2023 May 22. PMID: 37212697; PMCID: PMC10281126.

Introduction

Diarrhea apparent efficiency

In a randomized, double-blind, placebo-controlled trial of children with diarhea, the tested children were randomly divided into BLa80 probiotic intervention group and control group. After 72 hours of intervention, The marked and total effective rates of the lG were significantly higher than those of the CG.

Subjects

Dosage: Bifidobacterium lactis BLa80.5x109 CFU/sachet.2g/sachet

ltems	IG(n=58)	cG(n=53)	values	P values
No. of marked	31(53.4)	10(18.9)
efficiency[n(% )]*
No.of normal	18(31.0)	14(26.4)	21.6	<0.001
efficiency[n(%)]*<
No. of inefficiency[n(%)]*	9(15.6)	29(54.7)
No.of total efficiency[n(%)]*	49(84.4)1	24(45.3)	18.901	<0.001

In BLa80 group, the pathological changesof crypt injury, infiltration, ulcer and edema of colonic epithelium were alleviated

Boost immunity

BLa80 is capable of significantly reducing levels of inflammatory cytokines, including TNF-a, L-6, and lL-17, in the serum.
This suggests that BLa80 have anti-inflammatory properties and contribute to immune modulation.

BLa80 can requlate the intestinal immunity, reduce the expression of TNF- a in colon tissue, and increase the expression of interleukin(IL)

Sensitivity of Antibiotics

The diameter of inhibition zone of to 14 kinds of antibiotics was greater than 20mm,and 10 of them was greater than 30mm.It proves the safety of BLa80.

After the intervention, the serum TNF-a levels in both the BLa80prevention group and treatment group returned to normal, indicatingthe intervention of BLa80 reduced the levels of inflammatory factors

The content of lFN-y in the serum of the BLa80 prevention group wassignificantly higher than that of the normal control and treatmentgroup, indicating the BLa80 prevention group had a better immuneresponse to HRV.

BLa80 can reduce the expression of pro-inflammatory factors TNF-a, lL-6 and lL-17, and regulate intestinal immunity.

BLa80 significantly improves the therapeutic effect of diarrheal diseases in children, reduces the frequency of stool and improves stool characteristics.

BLa80 mitigates colitis by altering gut microbiota and alleviating inflammation.

BLa80 exerts a significant impact on the structure of the gut microbiota, effectively mitigating liver damage.

Reduces inflammation

The serum concentrations of pro-inflammatory cytokines TNF-a, lL-6 and lL-17 in UC group increased significantly, but compared with UC group, BLa80 group decreased significantly.

At the phylum level, composition analysis revealed that firmicutes and bacteroidetes were predominant in the gut microbiota of all three groups, the relative abundances differed between the groups.

Effect of BLa80 on the gut microbiota in mice with DSS-induced UC